Browse Penn-owned technologies available for licensing.
Squamous cell carcinoma is primarily caused by cumulative exposure to ultraviolet (UV) radiation over the course of life. There are approximately 700,000 new people in the United States annually, with the incidence of disease increasing up to 200 percent in the past three decades. This number is only projected to increase with aging populations, climate change, and breakdown of the ozone layer, which further increases our exposure to UV radiation.
Currently, treatments for actinic keratosis and squamous cell carcinoma in situ, precursors to squamous cell carcinoma, include:
Dr. Seykora and colleagues have demonstrated that topical application of commercially available small molecule kinase inhibitors to SRC kinases and downstream kinases, which are hyperactivated in tissue samples from human patients, provide efficacious targeted and localized therapy for actinic keratosis and squamous cell carcinoma in situ, precursors of squamous cell carcinoma, without inducing inflammation or crusting of skin.
Stage of Development:
Docket # V5056